GlassScriptPhysician profile
Rajesh Malik
NPI 1417997115
$14,099.94
in general payments reported to CMS, 2019-2025
31 companies · $7,180 in 2025
The $7,180 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $298 · 2021: $762 · 2022: $575 · 2023: $1,189 · 2024: $3,179 · 2025: $7,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,588 · Consulting Fee: $4,000 · Food and Beverage: $2,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,588.26 |
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,959.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,382.00 | 2019-2025 | Confianza, Esprit, Ensite Precision |
| Cagent Vascular INC | $2,668.46 | 2025 | Serrantor |
| Inari Medical, INC. | $1,141.35 | 2021-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $922.04 | 2021-2025 | |
| Novo Nordisk INC | $891.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $447.24 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $209.98 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $206.38 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $202.84 | 2019-2023 | |
| Medtronic Vascular, INC. | $149.26 | 2019 | |
| Amgen INC. | $140.69 | 2019-2023 | Repatha |
| Allergan, INC. | $86.50 | 2019-2020 | |
| Intuity Medical INC | $85.72 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Exact Sciences Corporation | $72.44 | 2024-2025 | Cologuard Collection Kit |
| Corium, LLC | $52.85 | 2023-2024 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $49.54 | 2024-2025 | Daxxify |
| Penumbra, INC. | $46.49 | 2023 | Smart Coil |
| Mannkind Corporation | $40.27 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.02 | 2022 | |
| Amarin Pharma, INC. | $30.33 | 2019 | |
| Lilly USA, LLC | $29.73 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Shield Therapeutics INC | $29.30 | 2023 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $28.22 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.27 | 2024 | Recorlev |
| Ani Pharmaceuticals, INC. | $20.82 | 2025 | Purified Cortrophin Gel |
| Acella Pharmaceuticals, LLC | $18.53 | 2024 | NP Thyroid 60 |
| Acell, INC. | $15.20 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.52 | 2022 | |
| Lundbeck LLC | $13.43 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.